Xiamen Changrong Investment Management

NAKI Therapeutics is a biopharmaceutical company specializing in research and development of Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy. Its innovative approach aims to effectively and safely eliminate cancer cells compared to existing treatments.

Ling Siwei is a chip designer focusing on IoT communications.

Amberstone Biosciences is a biotechnology company focused on discovering novel immunotherapies aimed at addressing challenging medical targets that traditional methods struggle to tackle. The company utilizes its proprietary microfluidics-powered AmberFlow drug-discovery platform, which allows for the analysis of single-cell function within a customizable microenvironment. This innovative approach, combined with the expertise of its team in immuno-oncology and single-cell assay biology, positions Amberstone to develop transformative therapeutic antibodies that cater to patients with unmet medical needs. Through creative partnerships and advanced technologies, Amberstone Biosciences seeks to overcome conventional limitations in therapeutic development, ultimately enhancing patient care and outcomes.

Eubulus is an early-stage company focusing on building a platform technology for therapeutic enhancement. The company specializes in Proteolysis- targeting chimeras (PROTACSs).

Anji Pharmaceuticals is focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.

VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases. VivaVision Biotech is dedicated to bringing new therapeutics to millions of patients suffering from chronic ocular or dermal inflammatory diseases.

Focus-X Therapeutics is a preclinical-stage biotechnology company specializing in the development of radiopharmaceuticals for cancer diagnosis and treatment. The company addresses unmet medical needs in oncology, particularly for solid tumors with low five-year survival rates. Focus-X Therapeutics employs a theragnostic approach, utilizing proprietary radioligand therapy (RLT) to deliver precise alpha or beta emitters that target and disrupt cancer cell DNA. By optimizing peptide ligand vectors, the company aims to innovate radioligand theranostic agents, offering healthcare professionals new therapeutic options in the fight against cancer.

Elgia Therapeutics is a biotechnology company focused on developing innovative therapies for chronic inflammatory and fibrotic diseases. The company employs novel approaches to drug discovery, utilizing throughput chemical screening and structure-based design to identify and develop small molecule inhibitors targeting untapped protein pathways. By understanding the role of metabolic stress in driving inflammation and fibrosis, Elgia Therapeutics aims to create effective treatments for debilitating chronic conditions. Its commitment to addressing these complex health issues positions the company as a leader in the field of therapeutics and pharmaceuticals.

Proviva Therapeutics is a pro-drug design platform for cytokines and other fusion proteins. It is committed to solving the problem of drug metabolism and the delivery of cytogenic drugs.

Shengshi Huaneng is committed to the collection, purification, and comprehensive utilization of methane-based greenhouse gases such as urban and rural agricultural and forestry biomass fermentation biogas, coal mine gas, and industrial tail gas, as well as distributed energy and other carbon emission reduction fields, to help China's carbon neutral development strategy.

ASI Semiconductor is a manufacturing company that develops and sells IC chips and related products.

Viva Biotech specializes in structure-based drug discovery services for biotechnology and pharmaceutical companies worldwide. Established in 2008, the company offers a range of platforms including fragment-based drug discovery, affinity selection mass spectrometry screening, and membrane protein targeted drug discovery. Its comprehensive services span from early-stage research to commercial drug delivery.

EO Company is a technology and industry innovation service platform specializing in the large health sector. It offers a range of core services, including health technology media, industry business conferences, and research consultation. Targeting businesses within the big health industry, EO Company provides high-quality online products such as industry content planning, video columns, and consulting services. The platform emphasizes connecting key players across the industry chain, focusing on high market attention and an international perspective. Overall, EO Company plays a pivotal role in promoting technological advancement and innovation in the health sector.

Chinese one-stop enterprise service platform.

Onlyou specializes in delivering finance and taxation solutions for large and medium-sized enterprises as well as administrative institutions. The company leverages advanced technologies such as artificial intelligence, cloud computing, and big data to provide efficient and intelligent tax and financial services. With a strong foundation in practical experience within the financial and taxation industries, Onlyou aims to simplify complex processes and offer comprehensive support to its clients.

Arthrosi Therapeutics is a biotechnology company specializing in the discovery and development of innovative drugs aimed at treating gout and chronic kidney disease. The company is engaged in clinical-stage research, focusing on therapies that effectively reduce uric acid levels and address complications such as flare-ups and tophi in gout patients. By advancing its drug development efforts, Arthrosi Therapeutics seeks to enable healthcare providers to better manage the symptoms and long-term joint damage associated with gout, ultimately improving patient outcomes.

Dogma Therapeutics is a biotechnology company based in the United States focused on developing innovative treatments for lowering blood lipid levels. The company specializes in creating orally bioavailable small molecule inhibitors targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). This approach aims to disrupt the interaction between PCSK9 and the LDL receptor, a challenging task due to the expansive binding interface. Dogma Therapeutics has achieved significant progress with picomolar affinity inhibitors, guided by high-resolution x-ray structures of their molecules bound to PCSK9.

wanmen.org is an online education platform that provides multiple courses.